PREZISTA or INTELENCE Switch Evaluation in Virologically Suppressed Patients Naive to Darunavir or Etravirine and Who Are Intolerant of Their Current or Prior Combination Antiretroviral Therapy Regimen: A Phase IV, Open-label, Multicentre Observational Trial

Trial Profile

PREZISTA or INTELENCE Switch Evaluation in Virologically Suppressed Patients Naive to Darunavir or Etravirine and Who Are Intolerant of Their Current or Prior Combination Antiretroviral Therapy Regimen: A Phase IV, Open-label, Multicentre Observational Trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Darunavir (Primary) ; Etravirine (Primary) ; Antiretrovirals; Ritonavir
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POISE
  • Sponsors Janssen Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jan 2013 Planned End Date changed from 1 Dec 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top